
The Event has Ended

AstraZeneca has provided a sponsorship grant towards this independent Programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence. except for the AstraZeneca sponsored symposia presentations.
NHS Medicines Optimisation Conference
“Medicines optimisation is about helping people to get the best outcomes from their medicines. It describes systems and processes used by staff, working in health and social care, which ensure that people receive the best possible care with medicines.” Health Education England
In March 2021 the NHS published the Network Contract Directed Enhanced Service Structured medication reviews and medicines optimisation guidance, this document outlines changes to the delivery of a structured medication review. PCNs must proactively consider all aspects of this guidance when planning, implementing and delivering structured medication reviews (SMR)
SMRs are designed to be a thorough clinical review of a patient’s medicines and detailed aspects of their health. They are delivered by aiding shared decision-making conversations with patients aimed at ensuring that their medication is working well for them.
The Convenzis NHS Medications Optimisation Virtual Conference aims to share key insights and updates following these forward-thinking initiatives and central guidance.
We will explore the “What has worked” and the “What hasn’t” and enable delegates to take part in key Q&A sessions with our panel of guest speakers from across industry and the NHS.
Over recent years there has been a further focus on the improvement of medicines optimisation across the healthcare ecosystem, other key areas of focus and improvement include:
Your Pass Includes:
Medication review βthe Isimpathy project
An overview of the 7 step medication review process and its evaluation in the I SIMPATHY project.
** 5 minute Q&A **
Collective Intelligence to support OPAT expansion
An overview of partnership working to understand current OPAT services and identify pathways for further expansion together with potential efficiency and productivity gains
The Discharge Medicines Service β Improving patient care through cross-sector working
The Discharge Medicines Service (DMS) was introduced as an essential service to the Community Pharmacy Contractual Framework in February 2021 and an indicator within the CQUIN guidance for 2022/23. It enables NHS Trusts to refer patients to their community pharmacy at discharge for medication guidance and support.
In this presentation we will share the aims of DMS and how a structured approach to implementation support, which engages stakeholders from across the ICS, can help to overcome challenges and significantly accelerate uptake. We will share the approach piloted in the Black Country which saw an increase in timely referrals and collaborative working with community pharmacy.
Managing the multi morbid Patient with Cardio-Renal Disease - This is a promotional symposium sponsored and organised by AstraZeneca
Case Study - AstraZeneca
Managing the multi morbid Patient with Cardio-Renal Disease - Dr Lavan Baskaran
This is a promotional symposium sponsored and organised by AstraZeneca
AstraZeneca has provided a sponsorship grant towards this independent Programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence. except for the AstraZeneca sponsored symposia presentations.
Comfort break
Findings from the 2022 Pharmacy and Medicines Optimisation Benchmarking Project
An introduction to the findings of the Pharmacy and Medicines Optimisation 2022 Benchmarking Project, covering key areas such as: clinical pharmacy, workforce, and medicines safety. The findings will support organisations to make evidence-based decisions and improvement plans to transform pharmacy services within their organisation.** 5 Minute Q&A **
Prescribing safety assessment (PSA): promoting basic competency of new doctors to prescribe and supervise the use of medicines
The PSA is the first national online prescribing assessment dedicated to testing the competence of new medical graduates to undertake their responsibilities as prescribers of medicines in a modern healthcare environment. This issue has assumed particular importance for healthcare providers around the world since it has been demonstrated a significant proportion of the prescriptions written by junior prescribers contain errors and that many patients experience avoidable adverse drug reactions. Healthcare providers and national authorities are increasingly seeking an assessment that can be a surrogate marker for prescribing competence. Drawing on the experience of the UK Prescribing Safety Assessment (PSA) over the last 10 years, this presentation will discuss the development, delivery, quality assurance and governance of the assessment and highlight some of the challenges encountered. It will highlight the major impact that this project has had in raising the profile of prescribing education and demonstrate how this approach to training might be utilised more widely.
End of Day